Oral compositions of H2-antagonists

Details Oral compositions of H2-antagonists Oral compositions of H2-antagonists

1995-02-02

1997-04-22

Henley, III, Raymond

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514400, 514471, 424683, 424684, 424687, A61K 31425, A61K 31415, A61K 3134, A61K 3312, A61K 3306, A61K 3308

Patent

active

056229801

ABSTRACT:
The present invention provides a pharmaceutical composition for the oral administration of an H.sub.2 -antagonist. The composition includes an H.sub.2 -antagonist and a silicate taste-masking agent capable of forming an adsorbate complex with the H.sub.2 -antagonist wherein the complex exhibits a non-bitter taste. The complex inhibits the release of the H.sub.2 -antagonist in the oral cavity.

REFERENCES:
patent: 3140978 (1964-07-01), Zentner
patent: 3248290 (1966-04-01), Zentner
patent: 3337402 (1967-08-01), Zentner
patent: 3337403 (1967-08-01), Zentner
patent: 3427379 (1969-02-01), Barry et al.
patent: 3432593 (1969-03-01), Shepard
patent: 3567819 (1971-03-01), Idson et al.
patent: 4327076 (1982-04-01), Puglia et al.
patent: 4711774 (1987-12-01), Denick, Jr. et al.
patent: 4716033 (1987-12-01), Denick, Jr.
patent: 4717565 (1988-01-01), Denick, Jr. et al.
patent: 4719228 (1988-01-01), Rawlins
patent: 4753800 (1988-06-01), Mozda
patent: 4758424 (1988-07-01), Denick, Jr. et al.
patent: 4758425 (1988-07-01), Denick, Jr. et al.
patent: 4761274 (1988-08-01), Denick, Jr. et al.
patent: 4859709 (1989-08-01), Rawlins
patent: 5057319 (1991-10-01), Gottwald et al.
patent: 5075114 (1991-12-01), Roche
patent: 5084278 (1992-01-01), Mehta
patent: 5169640 (1992-12-01), France et al.
patent: 5183829 (1993-02-01), Caldwell
patent: 5188839 (1993-02-01), Pearmain
patent: 5204118 (1993-04-01), Goldman et al.
patent: 5213794 (1993-05-01), Fritsch et al.
patent: 5219563 (1993-06-01), Douglas et al.
patent: 5225197 (1993-07-01), Bolt et al.
patent: 5229137 (1993-07-01), Wolfe
patent: 5260072 (1993-11-01), Roche et al.
patent: 5275823 (1994-01-01), France et al.
patent: 5288506 (1994-02-01), Spickett et al.
K. M. Koch, Abstract, Effect of Sapp on Ranitidine Bioavailability and Gastrointestinal Transit Time; Pharmaceutical Research 9:10, PPDM 8269, p. S-324 (1992).
J. T. Carstensen et al; Nature of Bonding in Montmorillonite Adsorbates I: Surface Adsorption; Journal of Pharmaceutical Sciences 60 pp. 733-735 (1971).
J. W. McGinity et al.; in Vitro Adsorption of Various Pharmaceuticals to Montmorillonite; Journal of Pharmaceutical Sciences pp. 896-902. (1980).
K. M. Koch et al.; Effect of Sodium Acid Pyrophosphate on Ranitidine Bioavailability and Gastrointestinal Transit Time; Pharmaceutical Research 10 pp. 1027-1030 (1993).
J. W. McGinity et al.; Influence of Monovalent and Divalent Electrolytes on Sorption of Neomycin Sulfate to Attapulgite and Montmorillonite Clays; Journal of Pharmaceutical Sciences 64 pp. 1566-1568 (1975).
K. Munzel; The Desorption of Medicinal Substances from Adsorbents in Oral Pharmaceutical Suspensions; Acta Pharmacologia Et Toxicologica 29 Suppl 3, (Copenh) (Denmark) pp. 81-87(1971).
J. W. McGinity et al.; Influence of Montmorillonite Clay on The Properties of Griseofulvin Tablets; Drug Development and Industrial Pharmacy 6(1), pp. 49-59 (1980).
J. W. McGinity et al.; Optimization of Slow-release Tablet Formulations Containing Montmorillonite 1. Properties of Tablets, Drug Development and Industrial Pharmacy, 6(4), pp. 399-410 (1980).
J. W. McGinity et al.; Sustained-Release Application of Montmorillonite Interaction with Amphetamine Sulfate, Journal of Pharmaceutical Sciences 66(1) pp. 63-66 (1977).

Affiliated with

Also associated with

Rating

Oral compositions of H2-antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oral compositions of H2-antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral compositions of H2-antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-342077